Lifecore Biomedical (LFCR) | Financial Analysis & Statements
Lifecore Biomedical Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2025Income Metrics
Revenue
31.1M
Gross Profit
7.8M
25.04%
Operating Income
-3.1M
-9.86%
Net Income
-10.0M
-32.12%
EPS (Diluted)
$-0.29
Balance Sheet Metrics
Total Assets
235.2M
Total Liabilities
245.7M
Shareholders Equity
-10.5M
Cash Flow Metrics
Operating Cash Flow
4.9M
Free Cash Flow
25.0K
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
Lifecore Biomedical Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 128.9M | 128.3M | 103.3M | 111.3M | 100.9M |
| Cost of Goods Sold | 88.6M | 86.4M | 75.3M | 72.2M | 61.9M |
| Gross Profit | 40.3M | 41.8M | 28.0M | 39.1M | 38.9M |
| Gross Margin % | 31.3% | 32.6% | 27.1% | 35.1% | 38.6% |
| Operating Expenses | |||||
| Research & Development | 8.3M | 8.6M | 8.7M | 7.8M | 6.7M |
| Selling, General & Administrative | 44.0M | 40.5M | 39.0M | 34.7M | 27.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 52.3M | 49.0M | 47.7M | 42.5M | 34.4M |
| Operating Income | -12.0M | -7.2M | -19.7M | -3.4M | 4.5M |
| Operating Margin % | -9.3% | -5.6% | -19.1% | -3.1% | 4.5% |
| Non-Operating Items | |||||
| Interest Income | 333.0K | - | 68.0K | 81.0K | 48.0K |
| Interest Expense | 22.2M | 18.1M | 17.6M | 15.5M | 8.9M |
| Other Non-Operating Income | -4.8M | 34.8M | -26.6M | -1.8M | -25.4M |
| Pre-tax Income | -38.7M | 9.5M | -63.9M | -20.7M | -29.8M |
| Income Tax | 43.0K | 183.0K | 308.0K | -5.2M | -6.4M |
| Effective Tax Rate % | 0.0% | 1.9% | 0.0% | 0.0% | 0.0% |
| Net Income | -38.7M | 12.0M | -99.6M | -116.7M | -32.3M |
| Net Margin % | -30.0% | 9.4% | -96.4% | -104.9% | -32.0% |
| Key Metrics | |||||
| EBITDA | -3.6M | -1.4M | -7.4M | 21.2M | 13.5M |
| EPS (Basic) | $-1.27 | $0.40 | $-3.32 | $-3.29 | $-1.11 |
| EPS (Diluted) | $-1.27 | $0.32 | $-3.32 | $-3.30 | $-1.12 |
| Basic Shares Outstanding | 34818906 | 30474000 | 29958000 | 29513000 | 29332832 |
| Diluted Shares Outstanding | 34818906 | 30474000 | 29958000 | 29513000 | 29332832 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Lifecore Biomedical Balance Sheet From 2022 to 2025
| Metric | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 17.5M | 8.3M | 8.5M | 19.1M | 991.0K |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 26.2M | 28.7M | 31.2M | 29.0M | 38.3M |
| Inventory | 29.1M | 32.3M | 40.0M | 40.8M | 36.0M |
| Other Current Assets | 1.9M | 1.5M | 1.4M | 4.9M | 2.1M |
| Total Current Assets | 82.3M | 85.7M | 81.0M | 93.9M | 116.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 2.4M | 4.3M | 5.6M |
| Goodwill | 27.8M | 27.8M | 32.0M | 32.0M | 32.0M |
| Intangible Assets | - | 4.2M | 4.2M | 4.2M | 4.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 8.7M | 10.8M | 3.8M | 2.9M | 15.7M |
| Total Non-Current Assets | 149.9M | 153.7M | 172.9M | 159.7M | 158.0M |
| Total Assets | 232.2M | 239.3M | 254.0M | 253.5M | 274.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 5.8M | 8.2M | 16.3M | 22.1M | 13.0M |
| Short-term Debt | 1.3M | 3.8M | 4.9M | 1.8M | 142.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.5M | 1.8M | - | - | 4.7M |
| Total Current Liabilities | 23.6M | 30.2M | 38.9M | 39.3M | 176.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 141.3M | 127.0M | 125.5M | 110.8M | 7.7M |
| Deferred Tax Liabilities | - | - | 543.0K | 380.0K | 126.0K |
| Other Non-Current Liabilities | 6.7M | 9.7M | 5.1M | 174.0K | 190.0K |
| Total Non-Current Liabilities | 222.8M | 207.8M | 203.8M | 218.5M | 10.3M |
| Total Liabilities | 246.4M | 238.0M | 242.6M | 257.8M | 186.9M |
| Equity | |||||
| Common Stock | 37.0K | 37.0K | 30.0K | 30.0K | 30.0K |
| Retained Earnings | -223.2M | -205.2M | -166.5M | -178.5M | -79.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -14.2M | 1.3M | 11.3M | -4.2M | 87.8M |
| Key Metrics | |||||
| Total Debt | 142.6M | 130.8M | 130.4M | 112.6M | 150.2M |
| Working Capital | 58.7M | 55.5M | 42.2M | 54.6M | -59.9M |
Balance Sheet Composition
Lifecore Biomedical Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -38.7M | 12.0M | -99.6M | -116.7M | -32.3M |
| Depreciation & Amortization | 8.0M | 8.9M | 13.2M | 18.1M | 19.9M |
| Stock-Based Compensation | 10.2M | 6.2M | 3.6M | 2.6M | 3.4M |
| Working Capital Changes | 1.2M | -6.0M | 20.3M | 318.0K | -2.6M |
| Operating Cash Flow | -1.7M | 36.8M | -61.1M | -103.0M | -19.6M |
| Investing Activities | |||||
| Capital Expenditures | -6.4M | -17.9M | -21.5M | -28.8M | -12.3M |
| Acquisitions | - | 0 | 16.7M | 73.5M | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | 0 | 0 | 45.1M | 0 |
| Investing Cash Flow | -6.4M | -17.9M | -4.8M | 80.0M | -12.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 131.0M | 149.6M | 181.4M | 75.1M | 270.0M |
| Debt Repayment | -145.8M | -146.8M | -178.3M | -130.5M | -262.5M |
| Financing Cash Flow | 7.7M | 6.8M | -14.9M | -101.1M | -151.8M |
| Free Cash Flow | -13.6M | -18.1M | -38.9M | -52.5M | -8.8M |
| Net Change in Cash | -375.0K | 25.7M | -80.8M | -124.1M | -183.7M |
Cash Flow Trend
Lifecore Biomedical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
56.23
Forward P/E
-6.30
Price to Book
-17.45
Price to Sales
1.51
PEG Ratio
-1.24
Profitability Ratios
Profit Margin
-23.78%
Operating Margin
8.18%
Return on Equity
312.34%
Return on Assets
-19.11%
Financial Health
Current Ratio
3.49
Debt to Equity
414.80
Beta
0.88
Per Share Data
EPS (TTM)
$-1.27
Book Value per Share
$-0.38
Revenue per Share
$3.46
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| LFCR | 184.4M | 56.23 | -17.45 | 312.34% | -23.78% | 414.80 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Aurora Cannabis | 200.4M | 20.75 | 0.49 | -15.51% | -22.51% | 17.79 |
| Anika Therapeutics | 221.7M | - | 1.48 | -6.71% | -9.64% | 18.30 |
| Organigram Holdings | 203.2M | 13.05 | 0.72 | 4.64% | 6.49% | 1.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.






